The proprietary HPV detection assay will amplify a specific region of the HPV genome of high risk HPV types, but not of low risk types.

The company said it has compared the analytical performance of its HPV assay with a commercially available HPV test which uses cytology samples.

The results demonstrated that the company’s assay had a sensitivity of 93% and a specificity of 96%, when compared to LBC test with sensitivity of 78% and a specificity of 86%.

Trovagene chief technology officer Charlie Rodi said the company’s urine-based test has the potential to determine male carrier status without resorting to methods that require scraping to collect cytology samples.